Ⅱ型糖尿病患者联用维格列汀与二甲双胍的疗效分析  

Efficacy analysis of Vildagliptin combined with Metformin in the treatment of patients with type 2 diabetes mellitus

作　　者：纪志尚[1] 刘秀英[1] JI Zhi-shang;LIU Xiu-ying(The Eighth People＇s Hospital of Qingdao City,Qingdao 266100,China)

机构地区：[1]青岛市第八人民医院,266100

出　　处：《中国实用医药》2018年第28期98-99,共2页China Practical Medicine

摘　　要：目的分析Ⅱ型糖尿病患者联用维格列汀与二甲双胍的疗效。方法 70例Ⅱ型糖尿病患者,随机分为对照组和观察组,每组35例。对照组给予二甲双胍治疗,观察组予以维格列汀联合二甲双胍治疗,观察比较两组患者的治疗前后血糖水平;治疗前后胰岛素(INS)及胰高血糖素样肽-1(GLP-1)水平;不良反应发生情况。结果治疗后,两组患者的空腹血糖(FPG)、糖化血红蛋白(HbA1c)、餐后2 h血糖(2 h PG)水平均低于治疗前,且观察组的FPG、HbA1c水平均低于对照组,差异具有统计学意义(P<0.05)。治疗后,两组患者的INS水平低于治疗前、GLP-1水平高于治疗前,差异具有统计学意义(P<0.05);观察组患者治疗后的INS(46.02±9.96)mU/L低于对照组的(52.47±7.93)mU/L、GLP-1(81.92±14.44)pmol/L高于对照组的(74.74±14.48)pmol/L,差异具有统计学意义(P<0.05)。两组患者在治疗过程中和治疗后均无明显不良反应发生。结论Ⅱ型糖尿病患者联用维格列汀与二甲双胍的疗效优于单独使用二甲双胍,在疗效提高的同时未出现不良反应,具有实际应用价值,值得临床推广。Objective To analyze the efficacy of Vildagliptin combined with Metformin in the treatment of patients with type 2 diabetes mellitus. Methods A total of 70 patients with type 2 diabetes mellitus were randomly divided into control group and observation group, 35 cases in each group. The control group was given Metformin for treatment, the observation group was given Vildagliptin combined with Metformin for treatment. The levels of blood glucose, insulin（INS） and glucagon like peptide-1（GLP-1） before and after treatment, the occurrence of adverse reactions between the two groups were compared. Results After treatment, the levels of fasting plasma glucose（FPG）, glycosylated hemoglobin（HbA1 c） and 2 h postprandial plasma glucose（2 h PG） in the two groups were significantly lower than those before treatment, and the levels of FPG and HbA1 c in the observation group were significantly lower than those in the control group, the differences were statistically significant（P0.05）. After treatment, the INS level of the two groups were significantly lower than those before treatment, the GLP-1 level of the two groups were significantly higher than those before treatment, the differences were statistically significant（P0.05）. The INS level of the observation group after treatment was（46.02± 9.96） mU/L, which was significantly lower than（52.47±7.93） mU/L of the control group, the GLP-1 level of the observation group after treatment was（81.92±14.44） pmol/L, which was significantly higher than（74.74± 14.48） pmol/L of the control group, the differences were statistically significant（P0.05）. No obvious adverse reactions occurred in the two groups during treatment and after treatment. Conclusion The efficacy of Vildagliptin combined with Metformin in the treatment of patients with type 2 diabetes mellitus is better than Metformin alone. No adverse reactions while the curative effect is improved. It has practical application value and is worthy of clinical promotion.

关 键 词：Ⅱ型糖尿病 维格列汀 二甲双胍 疗效 

分 类 号：R587.1[医药卫生—内分泌]